D.E. Shaw & Co
SPRY icon

D.E. Shaw & Co’s ARS Pharmaceuticals SPRY Stock Holding History

D.E. Shaw & Co’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,873
Closed -$95.3K – 5197
2026
Q1 		$95.3K Sell
11,873
-14,654
-55% -$140K ﹤0.01% 4289
2025
Q4 		$309K Sell
26,527
-7,692
-22% -$74.8K ﹤0.01% 4132
2025
Q3 		$344K Sell
34,219
-23,230
-40% -$333K ﹤0.01% 4042
2025
Q2 		$1M Buy
57,449
+23,652
+70% +$341K ﹤0.01% 3236
2025
Q1 		$425K Sell
33,797
-42,935
-56% -$517K ﹤0.01% 3584
2024
Q4 		$810K Sell
76,732
-3,816
-5% -$53.4K ﹤0.01% 3330
2024
Q3 		$1.17M Buy
80,548
+12,315
+18% +$146K ﹤0.01% 3162
2024
Q2 		$581K Buy
68,233
+30,056
+79% +$267K ﹤0.01% 3532
2024
Q1 		$390K Buy
+38,177
New +$285K ﹤0.01% 3603
2023
Q2 		– Sell
-24,302
Closed -$158K – 4532
2023
Q1 		$158K Sell
24,302
-19,396
-44% -$149K ﹤0.01% 3943
2022
Q4 		$373K Buy
43,698
+14,409
+49% +$93.5K ﹤0.01% 3995
2022
Q3 		$155K Sell
29,289
-62,834
-68% -$310K ﹤0.01% 4537
2022
Q2 		$391K Sell
92,123
-95,199
-51% -$332K ﹤0.01% 4236
2022
Q1 		$658K Sell
187,322
-62,694
-25% -$273K ﹤0.01% 4204
2021
Q4 		$1.67M Sell
250,016
-564
-0.2% -$4.58K ﹤0.01% 3521
2021
Q3 		$2.5M Buy
250,580
+40,453
+19% +$998K ﹤0.01% 2826
2021
Q2 		$6.49M Buy
210,127
+4,714
+2% +$151K 0.01% 1835
2021
Q1 		$8.96M Buy
+205,413
New +$9.72M 0.01% 1435

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

D.E. Shaw & Co's SPRY Position: Q2 2026 in Review

D.E. Shaw & Co sold out of ARS Pharmaceuticals (SPRY) in Q2 2026, closing a stake of 11,873 shares — an estimated $95.3K sold.

D.E. Shaw & Co first reported a position in SPRY in Q1 2021 and held it in 18 quarters. The position peaked at $8.96M in Q1 2021. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • D.E. Shaw & Co reported no remaining ARS Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • D.E. Shaw & Co sold 11,873 ARS Pharmaceuticals shares in Q2 2026, an estimated $95.3K.
  • D.E. Shaw & Co first reported a position in ARS Pharmaceuticals in Q1 2021 and held it in 18 quarters.
  • D.E. Shaw & Co's ARS Pharmaceuticals position peaked at $8.96M in Q1 2021.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.